+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Human Chorionic Gonadotropin Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4997499
The human chorionic gonadotropin market is projected to register a CAGR of nearly 7.6% over the forecast period (2022-2027).

The COVID-19 pandemic is an unprecedented health concern, adversely affecting communities, industries, businesses, and lives worldwide. Many companies have already received approval for their vaccines against the Sars-CoV-2 virus and are focusing their R&D on developing therapeutics against COVID-19.​ Due to COVID-19 restrictions worldwide, the footfall in the hospitals and clinics decreased significantly, negatively impacting the growth of the human chorionic gonadotropin market. For instance, according to the research study published in August 2020, titled “The global impact of COVID-19 on infertility services”, the participants in the study were from 97 countries, and in 82.5% of countries, assisted reproductive technology (ART) centers were shut down as they were not included in essential services or only a few were opened with limited access. In only 14.5% of countries, ART centers were operating without any restrictions, showing a negative impact of COVID-19 on fertility treatment procedures. Although, with the ongoing vaccinations and decreasing cases of COVID-19, the market is expected to regain normalcy over the coming years.

The growth of the human chorionic gonadotropin (HCG) market is attributed to the increasing burden of infertility and hypogonadism worldwide, which is driving the demand for HCG treatment. For instance, according to the September 2020 data of the World Health Organization, approximately 48 million couples and 186 million individuals are living with infertility globally. The major cause of infertility in females was disorders of the ovaries, uterus, and endocrine systems. In contrast, male infertility is majorly associated with the absence or low level of sperm and problem with the ejection of semen. Thus, due to the high burden of infertility, the demand for effective solutions is also increasing, which is driving the market’s growth as human chorionic gonadotropin (HCG) hormones are widely used in fertility treatment procedures.

In addition, increasing awareness about HCG among healthcare professionals and patients, coupled with the new product launches, is anticipated to boost the market’s growth over the forecast period. Human chorionic gonadotropin is used as a marker in cancer, including choriocarcinoma, seminoma, and germ cell tumors, which may augment the market’s growth over the coming years with the increasing cases of cancer. For example, as per the article published in January 2020 by David G. Grenache, HCG was initially developed as a test for pregnancy. However, HCG is now widely used to assess females with suspected ectopic pregnancy, along with other biomarkers when screening for fetal aneuploidies, and as a tumor marker for a variety of neoplasms.

Moreover, the continuous R&D in gonadotropin extraction and preparation, coupled with favorable initiatives by the government and non-government organizations, is expected to increase the demand for human chorionic gonadotropin products worldwide, thus positively impacting the market’s growth. However, the availability of substitutes and side effects related to human chorionic gonadotropin hormone are anticipated to hamper the market’s growth during the forecast period.

Key Market Trends

Female Infertility Treatment in the Application Segment is Anticipated to Grow at a Significant Rate Over the Forecast Period

Infertility is defined as the inability of the couple to get pregnant or the inability of the woman to carry a pregnancy to term. As the human chorionic gonadotropin (HCG) hormone plays a vital role after the formation of the embryo during pregnancy, the usage of HCG in infertility treatment gained traction in both men and women. Infertility in females can be for different reasons. According to the World Health Organization, the primary factors include tubal disorders like a blocked fallopian tube, uterine disorders, polycystic ovarian syndrome (PCOS), other follicular disorders, and endocrine system disorders. With the growing burden of infertility in females worldwide, the demand for effective treatment is increasing, which is expected to drive the growth of the segment over the forecast period. For instance, according to the research study published in December 2021, titled “Prevalence and associated factors of infertility among 20-49-year-old women in Henan Province, China”, the overall prevalence of infertility was 24.58%, while the prevalence of primary infertility among women was 6.54% and the prevalence of secondary infertility was 18.04%. Thus, due to the high prevalence of infertility among women, the use of HCG is expected to increase over the coming years, thus driving the market’s growth.

Further, the recombinant human chorionic gonadotropin products are anticipated to have significant growth due to the availability of different strengths and dosages for the individualization of therapy. The demand for naturally extracted HCG hormone products is also on the rise due to the launch of new products and high adoption, which may contribute to the segment’s growth during the forecast period.

North America is Anticipated to Register a Significant Growth

North America is anticipated to have significant market growth over the forecast period. The growth may be attributed to a well-established healthcare infrastructure, favorable reimbursement policies, and the growing burden of infertility in the region.

According to the December 2019 update of the Centers for Disease Control and Prevention (CDC), about 6.1 million women aged between 15 and 44 years who can get pregnant but are unable to conceive due to various factors may also be infertile. As per the same source, the percentage of impaired fecundity was 13.1% in women aged 15-49 years, 16.2% in married women aged 15-49 years, and about 8.8% of married women aged 15-49 years were infertile. Further, according to the May 2019 report of the Government of Canada, the cases of infertility have doubled since the 1980s and about 16% of couples in Canada experience infertility. In 3 out of 10 times, the problem is associated with men, while in 4 out 10, infertility is associated with women. This data shows a prevalence of infertility and impaired fecundity in the region, which may drive the demand for HCG for infertility treatment in the country, thus boosting the market’s growth in North America.

With rising awareness about infertility and its associated factors, the growing adoption of assisted reproductive technology (ART), and the development and launch of new products, the human chorionic gonadotropin (HCG) market is expected to grow further during the forecast period.

Competitive Landscape

The human gonadotropin market is moderately fragmented and competitive. Market players are focusing on new product launches, product innovations, and geographical expansion, which may drive the market’s growth. The key market players operating in the market include Merck KGaA, Fresenius SE & Co. KGaA, Lupin Limited, Sanzyme, and Merck & Co. Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 The Increasing Prevalence of Infertility and Hypogonadism
4.2.2 Changing Lifestyle and Awareness Regarding the Treatment of Infertility
4.3 Market Restraints
4.3.1 Availability of Substitutes
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Product
5.1.1 Natural Extracted
5.1.2 Recombinant
5.2 By Applications
5.2.1 Male Hypogonadism
5.2.2 Female Infertility Treatment
5.2.3 Oligospermic Treatment
5.2.4 Other Applications
5.3 By Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Sanzyme
6.1.2 Merck & Co. Inc.
6.1.3 Ferring BV
6.1.4 Fresenius Kabi AG
6.1.5 Sun Pharmaceutical Industries Ltd
6.1.6 Medix Biochemica (Lee BioSolutions Inc.)
6.1.7 Scripps Laboratories
6.1.8 Prospec-Tany Technogene Ltd
6.1.9 Biocare Medical LLC
6.1.10 Kamiya Biomedical Company

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Sanzyme
  • Merck & Co. Inc.
  • Ferring BV
  • Fresenius Kabi AG
  • Sun Pharmaceutical Industries Ltd
  • Medix Biochemica (Lee BioSolutions Inc.)
  • Scripps Laboratories
  • Prospec-Tany Technogene Ltd
  • Biocare Medical LLC
  • Kamiya Biomedical Company